<DOC>
	<DOCNO>NCT01672866</DOCNO>
	<brief_summary>This study evaluate whether simtuzumab ( formerly refer GS-6624 ) effective prevent histologic progression liver fibrosis clinical progression cirrhosis participant non-alcoholic steatohepatitis ( NASH ) . It consist 2 phase : - Randomized Double-Blind Phase - Open Label Phase ( optional )</brief_summary>
	<brief_title>Safety Efficacy Simtuzumab ( GS-6624 ) Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary Non-Alcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Adults chronic liver disease due NASH define macrovesicular steatosis involve &gt; 5 % hepatocytes liver biopsy associate lobular inflammation Stage 34 fibrosis Ishak score liver biopsy Exclusion cause liver disease include viral hepatitis alcoholic liver disease Must aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) â‰¤ 10 x Central Laboratory Upper Limit Normal ( clULN ) Must serum creatinine &lt; 2.0 mg/dL A negative serum pregnancy test require female childbearing potential All sexually active female childbearing potential must agree use protocol recommend method contraception intercourse throughout study 90 day follow last dose study medication Lactating female must agree discontinue nurse start study treatment Males , vasectomize , require use barrier contraception ( condom plus spermicide ) heterosexual intercourse screen study completion 90 day follow last dose study drug . Key Pregnant breast feed Cirrhosis liver Any history hepatic decompensation include ascites , hepatic encephalopathy variceal bleed Weight reduction surgery past 5 year Positive hepatitis C virus ( HCV ) RNA Positive HBsAg Alcohol consumption great 21oz/week male 14oz/week female Positive urine screen amphetamine , cocaine opiate ( i.e . heroin , morphine ) screening . Clinically significant cardiac disease History malignancy , nonmelanomatous skin cancer , within 5 year prior screen Major surgical procedure within 30 day prior screen presence open wound Known hypersensitivity investigation product formulation excipients History bleed diathesis within 6 month screen Unavailable followup assessment concern individual 's compliance protocol procedure ; Participation investigational trial drug device within 30 day prior screen BMI &lt; 18 kg/m^2 Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>NASH</keyword>
	<keyword>non cirrhotic</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>LOXL2</keyword>
	<keyword>Simtuzumab</keyword>
	<keyword>Nonalcoholic Steatohepatitis</keyword>
	<keyword>NAFLD</keyword>
	<keyword>Liver biopsy</keyword>
	<keyword>MRE</keyword>
</DOC>